UNSPSC 51312306: Bromazine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H20BrNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 202J683U97, chemically known as ethanamine, 2-((4-bromophenyl)phenylmethoxy)-n,n-dimethyl- but more generally known as bromazine hydrochloride, which bears US NIH Compound Identifier 2444. European Medicines Agency schedules Bromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00871MIG.

Most nations, for tariff and trade purposes, schedule bromazine hydrochloride under HS 29221980. SMILES: CN(C)CCOC(C1CCCCC1)C2CCC(CC2)BR.CL.

UNSPSC 51312306 Bromazine hydrochloride is a Commodity code, but state and local procurement activity recorded under this code does not reflect bromazine-specific purchases. Recent solicitations tagged to this code involve naloxone, safe drug deactivation systems, therapeutic pharmacy initiatives, and multi-source generic pharmaceuticals—none of which are bromazine products. The code shows minimal alignment between its nominal pharmaceutical ingredient scope and the actual work state and local governments are buying under it, suggesting either a data-tagging issue or that bromazine itself does not drive meaningful state and local procurement activity at present.

The three recent opportunities span health agencies and cooperative purchasing vehicles across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023, with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, due March 26, 2026, establishing multi-vendor contracts for generic pharmaceuticals and OTC products across participating states including Oregon, with contract effectiveness July 1, 2026. Activity under this code reflects state and local investment in opioid-response products and pharmacy supply-chain modernization rather than bromazine hydrochloride procurement.